C Castelo-Branco1, F Pons, J J Vicente, A Sanjuán, J A Vanrell. 1. Department of Gynecology and Obstetrics, Hospital Clínic i Provincial, School of Medicine, University of Barcelona, Spain. castelo@medicina.ub.es
Abstract
OBJECTIVE: To evaluate, in postmenopausal women who refusehormone replacement therapy (HRT), whether continuous administration of an osseinhydroxyapatite compound (OHC) reduces bone loss and protects from osteoporosis. STUDY DESIGN:Sixty postmenopausal women were included in an open study and were allocated to three groups. The first group (n = 19) received treatment consisting in 3.32 g/d of OHC per day, the second group (n = 21) received 2.5 g of calcium carbonate per day, and the third group (n = 20) was a treatment-free control group. Bone mineral density (BMD), assessed by dual x-ray absorptiometry, was measured prior to and at 12 and 24 months of treatment. RESULTS: Subjects on OHC therapy did not show significant changes related to baseline on bone mass across the study, whereas a significant decrease was detected in the calcium carbonate group during the second year (-3.7%, P < .05) and in the control group at the first and second BMD measurement (-3.5%, P < .05; -5.6%, P < .01). CONCLUSION: Continuous administration of OHC prevents bone loss in postmenopausal women, suggesting that this drug may be useful in the management of postmenopausal bone loss.
RCT Entities:
OBJECTIVE: To evaluate, in postmenopausal women who refuse hormone replacement therapy (HRT), whether continuous administration of an osseinhydroxyapatite compound (OHC) reduces bone loss and protects from osteoporosis. STUDY DESIGN: Sixty postmenopausal women were included in an open study and were allocated to three groups. The first group (n = 19) received treatment consisting in 3.32 g/d of OHC per day, the second group (n = 21) received 2.5 g of calcium carbonate per day, and the third group (n = 20) was a treatment-free control group. Bone mineral density (BMD), assessed by dual x-ray absorptiometry, was measured prior to and at 12 and 24 months of treatment. RESULTS: Subjects on OHC therapy did not show significant changes related to baseline on bone mass across the study, whereas a significant decrease was detected in the calcium carbonate group during the second year (-3.7%, P < .05) and in the control group at the first and second BMD measurement (-3.5%, P < .05; -5.6%, P < .01). CONCLUSION: Continuous administration of OHC prevents bone loss in postmenopausal women, suggesting that this drug may be useful in the management of postmenopausal bone loss.
Authors: Antonio Fernández-Pareja; Elena Hernández-Blanco; José Manuel Pérez-Maceda; Vicente José Riera Rubio; Javier Haya Palazuelos; José Manasanch Dalmau Journal: Clin Drug Investig Date: 2007 Impact factor: 2.859
Authors: Jakub Litak; Cezary Grochowski; Andrzej Rysak; Marek Mazurek; Tomasz Blicharski; Piotr Kamieniak; Piotr Wolszczak; Mansur Rahnama-Hezavah; Grzegorz Litak Journal: Materials (Basel) Date: 2022-01-26 Impact factor: 3.623